While toxicity during induction is still of concern, especially in the elderly patients, we conclude from these data that de-escalation of induction therapy in elderly primary central nervous
system lymphoma patients followed by maintenance treatment seems to be a promising treatment strategy.
The Nordic Lymphoma Group has conducted a phase ll trial in newly diagnosed primary central nervous
system lymphoma patients applying an age - adjusted multi-agent immunochemotherapy regimen, which in elderly patients included temozolomide maintenance treatment.
Not exact matches
MEG TIRRELL, NIGHTLY BUSINESS REPORT CORRESPONDENT: Since they were approved in 2014, drugs that stimulate the immune
system have been giving new hope to
patients with melanoma, kidney cancer,
lymphoma and other cancers, including famously to President Jimmy Carter, who credited the drug called Keytruda with shrinking tumors that had spread to his brain.
They are launching a clinical trial to evaluate the safety of their approach and gauge its effectiveness in
patients with
lymphoma, a cancer of the lymphatic
system.
The company is working on finding signatures of blood - based cancers, such as leukemia and
lymphoma, in
patients» immune
systems.
Dose - densified chemoimmunotherapy followed by systemic central nervous
system prophylaxis for younger high - risk diffuse large B - cell / follicular grade 3
lymphoma patients: results of a phase II Nordic Lymphoma Grou
lymphoma patients: results of a phase II Nordic
Lymphoma Grou
Lymphoma Group study.
The ride also supports a study to determine whether magnesium supplements can boost leukemia and
lymphoma patients» immune
systems.
Adding rituximab to MBVP induction chemotherapy does not improve outcomes for
patients with primary central nervous
system lymphoma.
The
lymphoma clinical trials investigate harnessing the immune
system of the
patient to help clear the tumor cells from the body.